Cargando…

Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries

BACKGROUND: Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiao, Bilcke, Joke, van der Velden, Alike W., Bruyndonckx, Robin, Coenen, Samuel, Bongard, Emily, de Paor, Muirrean, Chlabicz, Slawomir, Godycki-Cwirko, Maciek, Francis, Nick, Aabenhus, Rune, Bucher, Heiner C., Colliers, Annelies, De Sutter, An, Garcia-Sangenis, Ana, Glinz, Dominik, Harbin, Nicolay J., Kosiek, Katarzyna, Lindbæk, Morten, Lionis, Christos, Llor, Carl, Mikó-Pauer, Réka, Radzeviciene Jurgute, Ruta, Seifert, Bohumil, Sundvall, Pär-Daniel, Touboul Lundgren, Pia, Tsakountakis, Nikolaos, Verheij, Theo J., Goossens, Herman, Butler, Christopher C., Beutels, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290610/
https://www.ncbi.nlm.nih.gov/pubmed/36131214
http://dx.doi.org/10.1007/s10198-022-01521-2
_version_ 1785062526594056192
author Li, Xiao
Bilcke, Joke
van der Velden, Alike W.
Bruyndonckx, Robin
Coenen, Samuel
Bongard, Emily
de Paor, Muirrean
Chlabicz, Slawomir
Godycki-Cwirko, Maciek
Francis, Nick
Aabenhus, Rune
Bucher, Heiner C.
Colliers, Annelies
De Sutter, An
Garcia-Sangenis, Ana
Glinz, Dominik
Harbin, Nicolay J.
Kosiek, Katarzyna
Lindbæk, Morten
Lionis, Christos
Llor, Carl
Mikó-Pauer, Réka
Radzeviciene Jurgute, Ruta
Seifert, Bohumil
Sundvall, Pär-Daniel
Touboul Lundgren, Pia
Tsakountakis, Nikolaos
Verheij, Theo J.
Goossens, Herman
Butler, Christopher C.
Beutels, Philippe
author_facet Li, Xiao
Bilcke, Joke
van der Velden, Alike W.
Bruyndonckx, Robin
Coenen, Samuel
Bongard, Emily
de Paor, Muirrean
Chlabicz, Slawomir
Godycki-Cwirko, Maciek
Francis, Nick
Aabenhus, Rune
Bucher, Heiner C.
Colliers, Annelies
De Sutter, An
Garcia-Sangenis, Ana
Glinz, Dominik
Harbin, Nicolay J.
Kosiek, Katarzyna
Lindbæk, Morten
Lionis, Christos
Llor, Carl
Mikó-Pauer, Réka
Radzeviciene Jurgute, Ruta
Seifert, Bohumil
Sundvall, Pär-Daniel
Touboul Lundgren, Pia
Tsakountakis, Nikolaos
Verheij, Theo J.
Goossens, Herman
Butler, Christopher C.
Beutels, Philippe
author_sort Li, Xiao
collection PubMed
description BACKGROUND: Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. METHODS: Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers’ and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. RESULTS: The healthcare payers’ expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1–€35 per patient). CONCLUSION: Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers’ perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10198-022-01521-2.
format Online
Article
Text
id pubmed-10290610
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-102906102023-06-26 Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries Li, Xiao Bilcke, Joke van der Velden, Alike W. Bruyndonckx, Robin Coenen, Samuel Bongard, Emily de Paor, Muirrean Chlabicz, Slawomir Godycki-Cwirko, Maciek Francis, Nick Aabenhus, Rune Bucher, Heiner C. Colliers, Annelies De Sutter, An Garcia-Sangenis, Ana Glinz, Dominik Harbin, Nicolay J. Kosiek, Katarzyna Lindbæk, Morten Lionis, Christos Llor, Carl Mikó-Pauer, Réka Radzeviciene Jurgute, Ruta Seifert, Bohumil Sundvall, Pär-Daniel Touboul Lundgren, Pia Tsakountakis, Nikolaos Verheij, Theo J. Goossens, Herman Butler, Christopher C. Beutels, Philippe Eur J Health Econ Original Paper BACKGROUND: Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. METHODS: Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers’ and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. RESULTS: The healthcare payers’ expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1–€35 per patient). CONCLUSION: Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers’ perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10198-022-01521-2. Springer Berlin Heidelberg 2022-09-22 2023 /pmc/articles/PMC10290610/ /pubmed/36131214 http://dx.doi.org/10.1007/s10198-022-01521-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Li, Xiao
Bilcke, Joke
van der Velden, Alike W.
Bruyndonckx, Robin
Coenen, Samuel
Bongard, Emily
de Paor, Muirrean
Chlabicz, Slawomir
Godycki-Cwirko, Maciek
Francis, Nick
Aabenhus, Rune
Bucher, Heiner C.
Colliers, Annelies
De Sutter, An
Garcia-Sangenis, Ana
Glinz, Dominik
Harbin, Nicolay J.
Kosiek, Katarzyna
Lindbæk, Morten
Lionis, Christos
Llor, Carl
Mikó-Pauer, Réka
Radzeviciene Jurgute, Ruta
Seifert, Bohumil
Sundvall, Pär-Daniel
Touboul Lundgren, Pia
Tsakountakis, Nikolaos
Verheij, Theo J.
Goossens, Herman
Butler, Christopher C.
Beutels, Philippe
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries
title Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries
title_full Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries
title_fullStr Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries
title_full_unstemmed Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries
title_short Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries
title_sort cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled alic(4)e trial in 15 european countries
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290610/
https://www.ncbi.nlm.nih.gov/pubmed/36131214
http://dx.doi.org/10.1007/s10198-022-01521-2
work_keys_str_mv AT lixiao costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT bilckejoke costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT vanderveldenalikew costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT bruyndonckxrobin costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT coenensamuel costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT bongardemily costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT depaormuirrean costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT chlabiczslawomir costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT godyckicwirkomaciek costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT francisnick costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT aabenhusrune costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT bucherheinerc costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT colliersannelies costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT desutteran costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT garciasangenisana costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT glinzdominik costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT harbinnicolayj costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT kosiekkatarzyna costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT lindbækmorten costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT lionischristos costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT llorcarl costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT mikopauerreka costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT radzevicienejurguteruta costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT seifertbohumil costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT sundvallpardaniel costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT touboullundgrenpia costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT tsakountakisnikolaos costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT verheijtheoj costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT goossensherman costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT butlerchristopherc costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT beutelsphilippe costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries
AT costeffectivenessofaddingoseltamivirtoprimarycareforinfluenzalikeillnesseconomicevaluationalongsidetherandomisedcontrolledalic4etrialin15europeancountries